What are your top takeaways in Head & Neck Cancers from ASCO 2022?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?
Answer from: Radiation Oncologist at Academic Institution
In nasopharyngeal cancer, the group from Sun Yat-Sen University presented the results of a non-inferiority, randomized phase III study comparing RT alone vs RT concurrent with cisplatin for intermediate-risk patients (stage II and T3N0M0) (Ma et al., 2022 ASCO Annual Meeting, abstract #6000). They f...
Comments
Radiation Oncologist at Instituto Nacional del Cancer Chile Thank you so much for this review.
Answer from: Radiation Oncologist at Academic Institution
Tata Memorial Docetaxel Trial (6003)
Takeaway: Docetaxel improved DFS and OS compared to RT alone in cisplatin-ineligible patients.
Details:
356 cisplatin-ineligible patients with locally advanced disease needing definitive or adjuvant CRT.
Randomized to concurrent docetaxel 15 mg/m2 weekly f...
Comments
Radiation Oncologist at University of Michigan Agree with Dr. @Gary V. Walker regarding the ...
Thank you so much for this review.